Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin DeJesus

Showing results (21-30 of 167) with videos related to

Pageof 17
Sort By:
Antiviral Therapy|October 26, 2013
Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761)David A Margolis, Joseph J Eron, Edwin DeJesus, et al.
Antimicrobial Agents and Chemotherapy|September 24, 2008
Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification studyEdwin DeJesus, Michael S Gottlieb, Joseph C Gathe, et al.
The AIDS Reader|February 13, 2009
Antiretroviral therapy update from the 48th ICAAC/46th IDSA annual meetingBrian A Boyle, Calvin J Cohen, Edwin DeJesus, et al.
The AIDS Reader|July 1, 2008
Update on antiretroviral therapy: the 15th CROIBrian A Boyle, Calvin J Cohen, Edwin DeJesus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL)Nestor Sosa, Christina Hill-Zabala, Edwin Dejesus, et al.
Pulmonary Circulation|April 19, 2019
Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adultsEdwin DeJesus, Soundos Saleh, Sue Cheng, et al.
AIDS Research and Therapy|April 11, 2009
A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)Princy N Kumar, Patricia Salvato, Anthony LaMarca, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2005
Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trialMark S Sulkowski, Douglas T Dieterich, Edmund J Bini, et al.
Antiviral Therapy|August 17, 2010
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adultsEdwin DeJesus, Jacob P Lalezari, Olayemi O Osiyemi, et al.
HIV Clinical Trials|December 4, 2010
A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trialBenjamin Young, Thanes Vanig, Edwin Dejesus, et al.
Pageof 17

Showing results (21-30 of 167) with videos related to

Sort By:
Pageof 17
Antiviral Therapy|October 26, 2013
Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761)David A Margolis, Joseph J Eron, Edwin DeJesus, et al.
Antimicrobial Agents and Chemotherapy|September 24, 2008
Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification studyEdwin DeJesus, Michael S Gottlieb, Joseph C Gathe, et al.
The AIDS Reader|February 13, 2009
Antiretroviral therapy update from the 48th ICAAC/46th IDSA annual meetingBrian A Boyle, Calvin J Cohen, Edwin DeJesus, et al.
The AIDS Reader|July 1, 2008
Update on antiretroviral therapy: the 15th CROIBrian A Boyle, Calvin J Cohen, Edwin DeJesus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL)Nestor Sosa, Christina Hill-Zabala, Edwin Dejesus, et al.
Pulmonary Circulation|April 19, 2019
Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adultsEdwin DeJesus, Soundos Saleh, Sue Cheng, et al.
AIDS Research and Therapy|April 11, 2009
A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)Princy N Kumar, Patricia Salvato, Anthony LaMarca, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2005
Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trialMark S Sulkowski, Douglas T Dieterich, Edmund J Bini, et al.
Antiviral Therapy|August 17, 2010
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adultsEdwin DeJesus, Jacob P Lalezari, Olayemi O Osiyemi, et al.
HIV Clinical Trials|December 4, 2010
A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trialBenjamin Young, Thanes Vanig, Edwin Dejesus, et al.
Pageof 17